Xcout Intel
Slate Medicines competitors & alternatives
The 12 closest competitors and alternatives to Slate Medicines among pharmaceuticals companies — ranked by similarity to what Slate Medicines actually does, not by market-cap band.
Subscribe to see Slate Medicines’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Slate Medicines
Slate Medicines is a privately held biotechnology company advancing next-generation therapeutics for headache treatment, with headquarters located in Raleigh, North Carolina and Boston, Massachusetts.
Slate Medicines at a glance
Slate Medicines is a pharmaceuticals company headquartered in United States. Its most recent funding round, Series A, raised $130M in February 2026. Xcout tracks 18 named people at Slate Medicines, including Greg Oakes (CEO).
Slate Medicines leadership
- Greg OakesCEO
- Gregory OakesChief Executive Officer and Board Director
- Neil BuckleyCOO and president
- John Umstead, CPAChief Financial Officer
- Dr. Roger CadyChief Medical Officer
- Kenneth KoblanChief Scientific Officer
12 more named people on record for Slate Medicines, with roles, board committees and tenure — see the full roster →
Slate Medicines funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $130M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Slate Medicines news
Top 12 Slate Medicines competitors
Ranked by semantic similarity — how close each company is to Slate Medicines by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Epalex Corp. is a clinical-stage pharmaceutical company focused on developing breakthrough therapies for migraine and epilepsy, with its corporate headquarters in Mountain View, California.
Similar pharmaceuticals company
Novilla Pharmaceuticals is a biotechnology company headquartered in Cambridge, Massachusetts, developing a novel class of localized medicines designed by AI to treat pain. The firm focuses on targeted therapeutics that function only where needed within the body. It operates as a privately held startup with a small scientific team.
Similar pharmaceuticals company
Antares Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on developing first-in-class precision medicines.
Similar pharmaceuticals company
Mirata Pharmaceuticals, LLC develops non-addictive pain-relieving drugs as alternatives to prescription opioids. The company serves patients and physicians by creating medications that offer the analgesic benefits of opioids without their severe side effects and addictive properties.
Similar pharmaceuticals company
IX Biopharma is a Singapore-based specialty pharmaceutical company developing and commercializing medicines using its WaferiX fast-dissolving sublingual wafer drug-delivery technology. It has focused particularly on pain-management and central-nervous-system products, serving patients and healthcare providers through pharmaceutical products such as Wafermine.
Similar pharmaceuticals company
Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions. Its flagship product, ZTlido 1.8%, is a prescription-only topical lidocaine formulation designed to alleviate neuropathic pain, specifically that associated with post-herpetic neuralgia, a type of nerve pain occurring after a shingles infection. The company's development pipeline also features SP-102, known as SEMDEXA, a viscous corticosteroid gel administered via epidural injections. This candidate is currently in Phase 3 clinical trials, targeting lumbosacral radicular pain. Another investigational drug, SP-103, aims to treat low back pain and is progressing through Phase 2 clinical trials. Additionally, SP-104, an innovative low-dose, delayed-release naltrexone hydrochloride formulation, is in Phase 1 clinical development for managing fibromyalgia. Scilex Holding Company is headquartered in Palo Alto, California, and functions as a subsidiary of Sorrento Therapeutics, Inc.
Similar pharmaceuticals company
Cytogel Pharma, LLC is a biotechnology research company headquartered in Darien, Connecticut, focused on reinventing pain management.
Similar pharmaceuticals company
Dignify Therapeutics is a biotechnology company located in Research Triangle Park, North Carolina. The company focuses on developing pharmaceutical solutions to bolster bowel and bladder control for patients.
Similar pharmaceuticals company
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Pharmaceuticals, Biotechnology & Life Sciences
Tryptamine Therapeutics Limited is a public pharmaceuticals, biotechnology, and life sciences company based in Australia, trading under the ticker TYP.
Similar pharmaceuticals company
Emalex Biosciences is a drug discovery and biopharmaceutical company headquartered in Northbrook, Illinois, in the greater Chicago area. Created by Paragon Biosciences, the firm develops novel treatments for central nervous system disorders.
Similar pharmaceuticals company
Grünenthal is a global pharmaceutical company that researches, develops, and commercializes innovative treatments and medicines with a primary focus on pain management and related diseases. Operating as a science-based business, the company serves patients worldwide by delivering therapies for conditions such as chronic pain, rare diseases, and neurobiological indications.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Slate Medicines and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Slate Medicinesand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →